Molecular Formula | C19H24N2O |
Molar Mass | 296.41 |
Density | 1.24 |
Boling Point | 470.4±45.0 °C(Predicted) |
pKa | 9.77±0.33(Predicted) |
Storage Condition | RT, dry |
action | Palonosetron is a 5-HT3 receptor antagonist with high selectivity and affinity. Because of its structural differences from the first generation of 5-HT3 receptor antagonists, Palonosetron has at least 30 times the affinity for 5-HT3 receptors compared to other drugs of the same class. |
indication | Palonosetron is approved by the US FDA for acute and delayed CINV and PONV, with and dosage: 0.25mg was injected intravenously before chemotherapy and 0.075mg was injected intravenously before induction of anesthesia. At present, researchers at home and abroad have conducted more than 10 clinical trials on the efficacy and safety of palonosetron in preventing acute and delayed CINV and PONV. |
interaction | in vivo Palonosetron is eliminated by renal excretion and metabolism involving multiple CYP enzymes. Further in vitro studies have shown that Palonosetron is neither an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4/5(CYP2C19 not studied) nor induces CYP1A2, activity of CYP2D6 or CYP3A4/5. Therefore, the potential for significant clinical drug interactions with Palonosetron is low. |